30 May 2025
30 May 2025
The funding axe is just the latest hit to vaccine development by the HHS under RFK Jr.
Stealth BioTherapeutics has cut 30% of its workforce as it eyes a resubmission based on discussions with the FDA.
The withdrawal follows the discussions with the US FDA and topline outcomes from the Phase III trial.
Astellas will develop and commercialise the ADC, excluding mainland China, Macao, Hong Kong and the Taiwan region.
The strategic move is aimed at integrating automated, high-throughput gene synthesis into Regeneron's in-house laboratories.
Overcoming current limitations and expanding the reach of CAR-T therapeutics could unlock promising new treatment possibilities for solid tumour patients.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
